Interaction with CYP3A4 – Inhibitors Interaction with CYP3A4 – Inducers Interaction with – vasopressin receptor agonists Pharmacodynamic – – Interaction tolvaptan and combined administration of diuretics leading to dehydration and renal dysfunction Liver injury in ADPKD patients Anaphylaxis – Important urinary retention (in – potential patients with urinary outflow Allergic skin reactions – Raised intraocular – – pressure / glaucoma Interaction tolvaptan and – – combined administration of warfarin and antiplatelet agents in trial failure patients Interaction tolvaptan and – serum potassium concentration-increasing substances Pharmacodynamic – – Interaction tolvaptan and combined administration ACE-I possibly leading to dehydration and renal dysfunction Pharmacodynamic – – Interaction tolvaptan and combined administration ARB possibly leading to dehydration and dysfunction
Interaction with CYP3A4 Inhibitors – Interaction with CYP3A4 Inducers – Interaction with vasopressin receptor agonists – Pharmacodynamic Interaction tolvaptan and combined administration of diuretics leading to dehydration and renal dysfunction – – Liver injury in ADPKD patients Anaphylaxis – Important potential urinary retention (in patients with urinary outflow – Allergic skin reactions – Raised intraocular pressure / glaucoma – – Interaction tolvaptan and combined administration of warfarin and antiplatelet agents in failure patients – – Interaction tolvaptan and serum potassium concentration-increasing substances – Pharmacodynamic Interaction tolvaptan and combined administration ACE-I possibly leading to dehydration and renal dysfunction – – Pharmacodynamic Interaction tolvaptan and combined administration ARB possibly leading to dehydration and dysfunction – – trial